# Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography 28 Jan 26 publications # Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography Allan Levey Cyndy Cordell Douglas Beauregard Erik Johnson Jessie Nicodemus-Johnson John Dwyer Joshua Christensen Lynne Hughes Nicholas Seyfried Richard Mohs Robin Wolz Saima Rathore Alzheimers Disease Bio-Hermes [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/publications/biomarkers-in-patients-with-clinical-signs-of-mild-cognitive-impairment-or-mild-alzheimers-disease-but-without-amyloid-deposits-on-positron-emission-tomography/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/publications/biomarkers-in-patients-with-clinical-signs-of-mild-cognitive-impairment-or-mild-alzheimers-disease-but-without-amyloid-deposits-on-positron-emission-tomography/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/publications/biomarkers-in-patients-with-clinical-signs-of-mild-cognitive-impairment-or-mild-alzheimers-disease-but-without-amyloid-deposits-on-positron-emission-tomography/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/publications/biomarkers-in-patients-with-clinical-signs-of-mild-cognitive-impairment-or-mild-alzheimers-disease-but-without-amyloid-deposits-on-positron-emission-tomography/) ![Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography Jan 2026](/assets/blog-images/Biomarkers-in-patients-with-clinical-signs-of-mild-cognitive-impairment-or-mild-Alzheimers-disease-but-without-amyloid-deposits-on-positron-emission-tomography-Jan-2026__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp)### INTRODUCTION Alzheimer's disease (AD) study participants may present with cognitive impairment who do not have brain amyloid deposits (Aβ−). Identifying predictive biomarkers for non-amyloid-related CI may provide better screening tests for trials seeking only CI Aβ+ participants and new therapy targets. ### METHODS Analysis of the Bio-Hermes biomarker database identified subpopulations of clinically normal, CN Aβ− (n = 313), CI Aβ− (n = 296), and CI Aβ+ (n = 258), and CN Aβ+ (n = 84) participants. Comparative analysis of demographics, clinical assessments, biomarkers, cytokines, and proteomics results was conducted. ### RESULTS Subgroup comparison of CI Aβ− versus CN Aβ− found that neurofilament light most clearly differentiated CI Aβ− from CN Aβ− participants. No other biomarker analysis reached a level of differential significance. ### DISCUSSION Analyses showed many novel biomarkers do not differentiate CI Aβ− from CN Aβ−. New biomarkers are needed to best determine the neuropathology of the clinical presentation of AD. ### HIGHLIGHTS - NfL differentiated CN Aβ− versus cognitively impaired Aβ−. - Proteomics (two platforms) did not differentially assess cognitively impaired Aβ−-. - Many novel biomarkers did not differentially assess cognitively impaired Aβ−. - New biomarkers are needed to determine the neuropathology of AD clinical presentation. Click [here](https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71085) to view the full publication [ Back to Scientific Publications ](/news-and-resources/publications/) ### Recents ![Evaluating the Impact of Scanner Harmonisation with ComBat on Longitudinal Brain Volume Measures in Huntington’s Disease](/assets/blog-images/EHDN-2026-Poster__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 29 Oct 26 publications [Evaluating the Impact of Scanner Harmonisation with ComBat on Longitudinal Brain Volume Measures in Huntington’s Disease](/news-and-resources/publications/new-blog-evaluating-the-impact-of-scanner-harmonisation-with-combat-on-longitudinal-brain-volume-measures-in-huntingtons-disease-post/) [Neuromelanin-Sensitive MRI of the Substantia Nigra: Comparing TSE and MT-GRE Contrast](/news-and-resources/publications/contrast-ratio-assessment-of-the-substantia-nigra-in-neuromelanin-sensitive-mri/) [Improving Neuromelanin-sensitive MRI measurement ](/news-and-resources/publications/improving-neuromelanin-sensitive-mri-measurement/) [Further validation of IXI technology platform automation capabilities](/news-and-resources/publications/further-validation-of-ixi-technology-platform-automation-capabilities/) [Interchangeability of blood-based biomarkers and PET to identify Alzheimer's disease pathology](/news-and-resources/publications/interchangeability-of-blood-based-biomarkers-and-pet-to-identify-alzheimers-disease-pathology/) ### Library [November 2026](/news-and-resources/publications/archive/2026/11/) [October 2026](/news-and-resources/publications/archive/2026/10/) [September 2026](/news-and-resources/publications/archive/2026/09/) [July 2026](/news-and-resources/publications/archive/2026/07/) [June 2026](/news-and-resources/publications/archive/2026/06/) [May 2026](/news-and-resources/publications/archive/2026/05/) [April 2026](/news-and-resources/publications/archive/2026/04/) [March 2026](/news-and-resources/publications/archive/2026/03/) [February 2026](/news-and-resources/publications/archive/2026/02/) [January 2026](/news-and-resources/publications/archive/2026/01/) [2025](/news-and-resources/publications/archive/2025/) [2024](/news-and-resources/publications/archive/2024/) [2023](/news-and-resources/publications/archive/2023/) [2022](/news-and-resources/publications/archive/2022/) [2021](/news-and-resources/publications/archive/2021/) [2020](/news-and-resources/publications/archive/2020/) [2019](/news-and-resources/publications/archive/2019/)